Detalhe da pesquisa
1.
Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial.
Clin Cancer Res
; 30(4): 741-753, 2024 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38051741
2.
Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.
Eur J Cancer
; 150: 53-62, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33892407
3.
First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.
Eur J Cancer
; 157: 268-277, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34543871
4.
Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
J Clin Oncol
; 39(32): 3546-3560, 2021 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34347542